BioWorld

Dec. 5, 2006

Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma

A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today) Read More

Pfizer's Torcetrapib Failure Boosts Isis Market Chances

FM-VP4 Misses Main Endpoint; Forbes MediTech Falls By Half

Sangamo Gets VEGF-ZFP Rights From Edwards In Angiogenesis

Micromet Shares Take Ride On $10M Serono Payment

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026